JSJean-Paul Salameh

Jean-Paul Salameh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Paul Salameh has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis

    by Robert G. Adamo, Christian B. van der Pol, Mostafa Alabousi, Eric Lam, Jean-Paul Salameh, Nicole Abedrabbo, Emily Lerner, Haresh Naringrekar, Mustafa R. Bashir, Andreu F. Costa, et al.

    This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.


  • Open Access

    Assessing Adherence to the PRISMA-DTA Guideline in Diagnostic Test Accuracy Systematic Reviews: A Five-Year Follow-up Analysis

    by Jean-Paul Salameh, David Moher, Trevor A McGrath, Robert A Frank, Anahita Dehmoobad Sharifabadi, Nabil Islam, Eric Lam, Robert Adamo, Haben Dawit, Mohammed Kashif Al-Ghita, et al.

    Background: We evaluated reporting of diagnostic test accuracy (DTA) systematic reviews using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-DTA and PRISMA-DTA for abstracts. Methods: We searched MEDLINE for recent DTA systematic reviews (September 2023–Mar 2024) to achieve a sample size of 100. Analyses evaluated adherence to PRISMA-DTA (and abstracts), on a per-item basis. Association of reporting with journal, country, impact factor (IF), index-test type, subspecialty area, use of supplemental material, PRISMA citation, word count, and PRISMA adoption was evaluated. Comparison to the baseline evaluation from 2019 was done. Protocol: https://doi.org/10.17605/OSF.IO/P25TE. Results: Overall adherence (n = 100) was 78% (20.3/26.0 items, SD = 2.0) for PRISMA-DTA and 52% (5.7/11.0 items, SD = 1.6) for abstracts. Infrequently reported items (<33% of studies): eligibility criteria, definitions for data extraction, synthesis of results, and characteristics of the included studies. Infrequently reported items in abstracts were characteristics of the included studies, strengths and limitations, and funding. Reporting completeness for full text was minimally higher in studies in higher IF journals [20.7 vs 19.8 items; 95% confidence interval (95%CI) (0.09; 1.77)], as well as studies that cited PRISMA [21.1 vs 20.1 items; 95%CI (0.04; 1.95)], or used supplemental material (20.7 vs 19.2 items; 95%CI (0.63; 2.35)]. Variability in reporting was not associated with author country, journal, abstract word count limitations, PRISMA adoption, structured abstracts, study design, subspecialty, open-access status, or index test. No association with word counts was observed among full text or abstracts. Compared to the baseline evaluation, reporting was improved for full texts [71% to 78%; 95%CI (1.18; 2.26)] but not for abstracts [50% to 52%; 95%CI (−0.20; 0.60)]. Conclusions: Compared to the baseline evaluation published in 2019, we observed modest improved adherence to PRISMA-DTA and no improvement in PRISMA-DTA for abstracts reporting.


  • Individual Participant Data Meta-Analyses for Diagnostic Accuracy Research: Challenges and Lessons Learned from the LI-RADS IPD Group

    by Andreu F. Costa, Matthew D. F. McInnes, Christian B. van der Pol, Eric Lam, Haben Dawit, Jean-Paul Salameh, Brooke Levis, Mustafa R. Bashir


  • LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis

    by Haben Dawit, Eric Lam, Matthew D. F. McInnes, Christian B. van der Pol, Mustafa R. Bashir, Jean-Paul Salameh, Brooke Levis, Claude B. Sirlin, Victoria Chernyak, Sang Hyun Choi, et al.

    Background The independent contribution of each Liver Imaging Reporting and Data System (LI-RADS) CT or MRI ancillary feature (AF) has not been established. Purpose To evaluate the association of LI-RADS AFs with hepatocellular carcinoma (HCC) and malignancy while adjusting for LI-RADS major features through an individual participant data (IPD) meta-analysis. Materials and Methods Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus were searched from January 2014 to January 2022 for studies evaluating the diagnostic accuracy of CT and MRI for HCC using LI-RADS version 2014, 2017, or 2018. Using a one-step approach, IPD across studies were pooled. Adjusted odds ratios (ORs) and 95% CIs were derived from multivariable logistic regression models of each AF combined with major features except threshold growth (excluded because of infrequent reporting). Liver observation clustering was addressed at the study and participant levels through random intercepts. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2. Results Twenty studies comprising 3091 observations (2456 adult participants; mean age, 59 years ± 11 [SD]; 1849 [75.3%] men) were included. In total, 89% (eight of nine) of AFs favoring malignancy were associated with malignancy and/or HCC, 80% (four of five) of AFs favoring HCC were associated with HCC, and 57% (four of seven) of AFs favoring benignity were negatively associated with HCC and/or malignancy. Nonenhancing capsule (OR = 3.50 [95% CI: 1.53, 8.01]) had the strongest association with HCC. Diffusion restriction (OR = 14.45 [95% CI: 9.82, 21.27]) and mild-moderate T2 hyperintensity (OR = 10.18 [95% CI: 7.17, 14.44]) had the strongest association with malignancy. The strongest negative associations with HCC were parallels blood pool enhancement (OR = 0.07 [95% CI: 0.01, 0.49]) and marked T2 hyperintensity (OR = 0.18 [95% CI: 0.07, 0.45]). Seventeen studies (85%) had a high risk of bias. Conclusion Most LI-RADS AFs were independently associated with HCC, malignancy, or benignity as intended when adjusting for major features. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Crivellaro in this issue.


  • Open Access

    Pre-operative Spine Tumor Embolization: Clinical Outcomes and Effect of Embolization Completeness

    by Nima Omid-Fard, Jean-Paul Salameh, Matthew DF McInnes, Charles G Fisher, Manraj Ks Heran

    Background and Purpose To assess the association between the impact of the completeness of pre-operative spine tumour embolization and clinical outcomes including estimated blood loss (EBL), neurological status, and complications. Materials and Methods Retrospective chart review of all preoperative spine tumour embolization procedures performed over 11 years by a single operator (2007-2018) at Vancouver General Hospital, on 40 consecutive patients (mean age 58; 77.5% males) with 42 embolization procedures, of which surgery was done en bloc in 22 cases and intralesional in the remaining 20. A multivariable negative binomial regression model was fit to examine the association between EBL and surgery type, tumour characteristics, embolization completeness and operative duration. Results Among intralesional surgeries, complete versus incomplete embolization was associated with reduced blood loss (772 vs 1428 mL, P < 0.001). There was no statistically significant difference in neurological outcomes or complications between groups. Highly vascular tumours correlated with greater blood loss than their less vascular counterparts, but tumour location did not have a statistically significant effect. Conclusion This study provides early evidence in support of our hypothesis that complete as opposed to incomplete tumour embolization correlates with reduced blood loss in intralesional surgeries. Randomized control trials with larger samples are necessary to confirm this benefit and to ascertain other potential clinical benefits.

  • Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis

    by Stacy M. Goins, Hanyu Jiang, Christian B. van der Pol, Jean-Paul Salameh, Eric Lam, Robert G. Adamo, Matthew D. F. McInnes, Andreu F. Costa, An Tang, Ayman S. Alhasan, et al.

    Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.


  • Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018

    by Stacy M. Goins, Robert G. Adamo, Eric Lam, Andreu F. Costa, Christian B. van der Pol, Jean-Paul Salameh, Haben Dawit, Matthew D. F. McInnes, Mustafa R. Bashir


  • How to Critically Appraise and Interpret Systematic Reviews and Meta-Analyses of Diagnostic Accuracy: A User Guide

    by Robert A. Frank, Jean-Paul Salameh, Nayaar Islam, Bada Yang, Mohammad Hassan Murad, Reem Mustafa, Mariska Leeflang, Patrick M. Bossuyt, Yemisi Takwoingi, Penny Whiting, et al.

    This article provides a practical guide for clinicians and radiologists to critically evaluate diagnostic accuracy systematic reviews when using them to inform clinical decisions. Systematic reviews of diagnostic accuracy studies can provide the best available evidence to inform decisions regarding the use of a diagnostic test. In this guide, the authors provide a practical ...


  • Chest CT Findings in Marijuana Smokers

    by Luke Murtha, Paul Sathiadoss, Jean-Paul Salameh, Matthew D. F. Mcinnes, Giselle Revah

    In this case-control study of marijuana smokers, nonsmokers, and tobacco-only smokers, smoking marijuana was associated with paraseptal emphysema, bronchiectasis, bronchial wall thickening, and air... Background Global consumption of marijuana is increasing, but there is a paucity of evidence concerning associated lung imaging findings. Purpose To use chest CT to investigate the effects of marij...


  • Open Access

    Radiomics artificial intelligence modelling for prediction of local control for colorectal liver metastases treated with radiotherapy

    by Ricky Hu, Ishita Chen, Jacob Peoples, Jean-Paul Salameh, Mithat Gönen, Paul B. Romesser, Amber L. Simpson, Marsha Reyngold